Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/oo, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$

.BN		
7 164	440 859	
Ve (the	e entity) give ASX the following	information.
	- All issues t complete the relevant sections (attach	sheets if there is not enough space).
1	⁺ Class of ⁺ securities issued or to be issued	Fully paid ordinary shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	156,250,000
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares

Name of entity
Schrole Group Ltd

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
	meerese pulment	
5	Issue price or consideration	\$0.008 (0.8 cents) per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	To raise additional funds to increase the Company's business development and in-house software development capability to support the rollout of strategic initiatives, including launching new revenue generating products
6a	In the outine on talinible outine	Yes
Oa .	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	ies
	If Yes, complete sections 6b – 6h	
	in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	23 May 2018
6c	Number of *securities issued without security holder approval under rule 7.1	93,112,977
6d	Number of *securities issued with security holder approval under rule 7.1A	63,137,023

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	Nil	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	Yes VWAP date: 26 April Issue date: 3 May 201 15 day VWAP: \$0.010 75% of VWAP: \$0.000 Discount to VWAP: Source: Orient Capit	19 1603 17952 24.5%
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1: 1,592, 7.1A: 1,592, Total: 1,592,	О
7	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	3 May 2019	
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	Number 554,316,176	+Class Fully paid ordinary shares
9	Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	233,304,055	Fully paid ordinary shares escrowed for 24 months from quotation

⁺ See chapter 19 for defined terms.

shares subject to Class B milestones as detailed in Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation C Class performance shares subject to Class C milestones as detailed in Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation 4,720,000 Performance Rights with a nil exercise price expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue years from issue	93,000,000	B Class performance
milestones as detailed in Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation 150,000,000 C Class performance shares subject to Class C milestones as detailed in Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation 4,720,000 Performance Rights with a nil exercise price expiring 5 years from issue 13,560,000 Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 22,600,000 Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 25,707,927 Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24	93,000,000	_
Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation C Class performance shares subject to Class C milestones as detailed in Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation Performance Rights with a nil exercise price expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 22,600,000 Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 25,707,927 Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		
August 2017, expiring 5 years from issue, escrowed for 24 months from quotation C Class performance shares subject to Class C milestones as detailed in Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation 4,720,000 Performance Rights with a nil exercise price expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 22,600,000 Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 25,707,927 Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		
years from issue, escrowed for 24 months from quotation C Class performance shares subject to Class C milestones as detailed in Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation Performance Rights with a nil exercise price expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		-
for 24 months from quotation C Class performance shares subject to Class C milestones as detailed in Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation 4,720,000 Performance Rights with a nil exercise price expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 22,600,000 Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 25,707,927 Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		
quotation C Class performance shares subject to Class C milestones as detailed in Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation 4,720,000 Performance Rights with a nil exercise price expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 22,600,000 Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 25,707,927 Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		
C Class performance shares subject to Class C milestones as detailed in Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation 4,720,000 Performance Rights with a nil exercise price expiring 5 years from issue 13,560,000 Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 22,600,000 Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 25,707,927 Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		
shares subject to Class C milestones as detailed in Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation 4,720,000 Performance Rights with a nil exercise price expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 22,600,000 Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 25,707,927 Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24	150,000,000	
milestones as detailed in Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation 4,720,000 Performance Rights with a nil exercise price expiring 5 years from issue 13,560,000 Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 22,600,000 Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 25,707,927 Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24	150,000,000	
Prospectus dated 18 August 2017, expiring 5 years from issue, escrowed for 24 months from quotation Performance Rights with a nil exercise price expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 22,600,000 Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 25,707,927 Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		· ·
August 2017, expiring 5 years from issue, escrowed for 24 months from quotation 4,720,000 Performance Rights with a nil exercise price expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 22,600,000 Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 25,707,927 Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		
years from issue, escrowed for 24 months from quotation 4,720,000 Performance Rights with a nil exercise price expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 22,600,000 Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 25,707,927 Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		•
for 24 months from quotation 4,720,000 Performance Rights with a nil exercise price expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		
quotation Performance Rights with a nil exercise price expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 25,707,927 Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		-
Performance Rights with a nil exercise price expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		-
nil exercise price expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24	4 720 000	•
5 years from issue Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24	4,720,000	_
Performance Rights with a nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		
nil exercise price and with Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 22,600,000 Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 25,707,927 Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		
Tranche B Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 22,600,000 Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24	13,560,000	_
Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 22,600,000 Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		
as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 22,600,000 Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue 25,707,927 Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		
Company's prospectus dated 3 July 2018, expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		0
dated 3 July 2018, expiring 5 years from issue Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		
performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		
Performance Rights with a nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		
nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		5 years from issue
nil exercise price and with Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24	22,600,000	Performance Rights with a
Tranche C Performance Rights vesting conditions as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24	•	_
as detailed in the Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		
Company's prospectus dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		Rights vesting conditions
dated 3 July 2018, expiring 5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		as detailed in the
5 years from issue Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		Company's prospectus
Vendor options with exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		
exercise price of \$0.04 and expiring 3 years from issue date, escrowed for 24		5 years from issue
expiring 3 years from issue date, escrowed for 24	25,707,927	
date, escrowed for 24		
· · · · · · · · · · · · · · · · · · ·		
months from quotation.		1 1

Number	+Class
71,292,073	Unlisted options with
	exercise price of \$0.04 and
	expiring 3 years from issue
	date, escrowed for 12
	months from issue;
28,250,000	Unlisted options with
	exercise price of \$0.02,
	expiring 3 years from issue
	date, escrowed for 24
	months from quotation
50,000,000	Unlisted options with
	exercise price of \$0.03,
	expiring 3 years from issue
	date, escrowed for 24
	months from quotation
21,750,000	Unlisted options with
	exercise price of 0.02,
	expiring 3 years from
	quotation, escrowed for 12
	months from issue
7,000,000	Unlisted options with
	exercise price of \$0.03,
	expiring 3 years after issue
	date, escrowed for 24
	months from quotation
7,000,000	Unlisted options with
	exercise price of \$0.04
	(and vesting only if 10-day
	VWAP of the Company's
	share is \$0.04), expiring 3
	years after issue date,
	escrowed 24 months from
	quotation

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A		

Part 2 - Pro rata issue - NOT APPLICABLE

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- Type of *securities (tick one)
- (a) +Securities described in Part 1

⁺ See chapter 19 for defined terms.

(b)	All other ⁺ securities
	Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible
	securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to docum	e you are providing the information or
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities

Entities that have ticked box 34(b) – questions 38-42 not applicable

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

• Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.

- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	Model Date:	3 May 2019
	(Director/Company secretary)	
Print name:	Nick Allan	

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities – Not applicable

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base fig capacity is calculated	Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	580,050,231		
 Add the following: Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval Number of partly paid +ordinary securities that became fully paid in that 12 month period 	47,000,000 [Issued 27 Sep 2018 on conversion of Series A Performance Shares issued under IPO Prospectus, under LR7.2 Exception 4] 4,320,000 [Issued 12 Nov 2018 on conversion of performance rights issued under Cleansing Prospectus, under 7.2 Exception 9]		
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items Subtract the number of fully paid ordinary securities cancelled during that 12 month period	0		
"A"	631,370,231		

Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]	
Multiply "A" by 0.15	94,705,534	
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule	
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	93,112,977 [Subject of this release]	
Under an exception in rule 7.2		
• Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	93,112,977	
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1	-	
"A" x 0.15	94,705,534	
Note: number must be same as shown in Step 2		
Subtract "C"	93,112,977	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	1,592,557	
	[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	631,370,231	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	63,137,023	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	63,137,023 [Subject of this release]	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	63,137,023	

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10 Note: number must be same as shown in Step 2	63,137,023
Subtract "E" Note: number must be same as shown in Step 3	63,137,023
<i>Total</i> ["A" x 0.10] – "E"	0 Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.